BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Also, mutations in the kinase domain of Abl within Bcr/Abl have been previously reported to confer Imatinib-resistance in CML patients [11,13-21] and a recent study showed that certain other mutations in Abl can make cells nilotinib-resistant [29,30].